ClinicalTrials.gg
CompletedNCT07931287Updated Nov 12, 2026

Different Graft Materials in Penile Curvature

An interventional study of Buccal Mucosa grafting and Fascia Lata grafting in Peyronie's Disease, sponsored by Tanta University. Completed at 1 site in Egypt. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled May 2025, registered Nov 2026).
Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Limited comparative evidence is available regarding the outcomes of buccal mucosa versus fascia lata grafts in the surgical management of Peyronie's disease. Therefore, the present study was conducted to compare the clinical and functional outcomes of buccal mucosa and fascia lata grafting in patients undergoing reconstructive surgery for Peyronie's disease.

02

Conditions studied

  • Peyronie's Disease

Browse trials for

03

In context

Penile Induration

48 studies on the registry are indexed under Penile Induration; 10 are open to participants now.

This study's enrollment of 40 is close to the median of 40 across 40 interventional studies indexed under Penile Induration.

Browse Penile Induration studies →

Lead sponsor

Tanta University is the lead sponsor of 1,013 studies on the registry; 321 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult age group (more than18 years)
  • Stable phase of the disease (6 months free of pain)
  • Severe penile curvature (more than 60 degrees)
  • Complex deformities like hourglass and hinge deformities

Exclusion criteria

Exclusion Criteria:

  • Pediatric patients
  • History of Erectile dysfunction
  • Penile curvature less than 60 degrees
  • Active phase of the disease
  • Bleeding disorder
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Buccal Mucosa graft

    Procedure: Buccal Mucosa grafting

  • Active comparator
    Fascia Lata graft

    Procedure: Fascia Lata grafting

Interventions

  • ProcedureBuccal Mucosa grafting

    Incision of plaque and buccal mucosa grafting

  • ProcedureFascia Lata grafting

    Incision of plaque and fascia lata grafting

06

What researchers measure

Primary outcomes

  1. Straight penis or a residual penile curvature less than 15 degrees

    Time frame: Up to 6 months postoperatively

Secondary outcomes

  1. Complications of both techniques (mainly failure rate, donor site complications and erectile dysfunction)

    Time frame: Up to 6 months postoperatively

07

Study locations

1 site
  • Faculty of Medicine, Tanta University
    Tanta, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Dec 2025, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 12, 2026
StartActual
May 1, 2025
Primary completionActual
Dec 1, 2025
CompletionActual
May 1, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07931287
Lead sponsor
Tanta University
Responsible party
Mahmoud Elrefaey (Principal Investigator, Tanta University) — Principal investigator
First posted
Nov 12, 2026
Start date
May 1, 2025
Primary completion
Dec 1, 2025
Completion
May 1, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion